CD10 is a cell surface metalloendopeptidase that cleaves and degrades many secreted physiologically active peptides by its enzymatic activity. Although CD10 expression has been found in various types of cells, its expression is increased in several cancers, including renal cancer. In this study, the antitumor activity of a novel anti-human CD10 monoclonal antibody (mAb) was investigated. A defucosylated mouse IgG2a version of C10Mab-31 (31-mG2a-f) was created from an anti-CD10 mAb, C10Mab-31 (IgG1, kappa). Both C10Mab-31 and 31-mG2a-f specifically reacted with endogenous CD10 in renal cancer cells, VMRC-RCW, with the dissociation constant (KD) values of 6.3 × 10−9 M and 1.1 × 10−9 M, respectively, indicating high binding affinity. To further examine the anti-CD10 mAb-mediated effector functions, the antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) were examined. The 31-mG2a-f significantly exhibited ADCC and CDC against VMRC-RCW cells in vitro. Furthermore, 31-mG2a-f exhibited antitumor activities in mouse xenografts of VMRC-RCW cells. These results suggest that 31-mG2a-f exerts antitumor activities against CD10-expressing renal cancers and could be a valuable therapeutic candidate for treating them.
SiegelRL, MillerKD, FuchsHE, and JemalA: Cancer statistics, 2022. CA Cancer J Clin, 2022; 72:7–33.
3.
SungH, FerlayJ, SiegelRL, LaversanneM, SoerjomataramI, JemalA, and BrayF: Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 2021; 71:209–249.
4.
LavacchiD, PellegriniE, PalmieriVE, DoniL, MelaMM, Di MaidaF, AmedeiA, PillozziS, CariniM, and AntonuzzoL: Immune checkpoint inhibitors in the treatment of renal cancer: Current state and future perspective. Int J Mol Sci, 2020; 21:4691.
5.
GarjeR, AnJ, GrecoA, VaddepallyRK, and ZakhariaY: The future of immunotherapy-based combination therapy in metastatic renal cell carcinoma. Cancers (Basel), 2020; 12:143.
6.
RoquesBP, NobleF, DaugéV, Fournié-ZaluskiMC, and BeaumontA: Neutral endopeptidase 24.11: Structure, inhibition, and experimental and clinical pharmacology. Pharmacol Rev, 1993; 45:87–146.
7.
Maguer-SattaV, BesançonR, and Bachelard-CascalesE: Concise review: Neutral endopeptidase (CD10): A multifaceted environment actor in stem cells, physiological mechanisms, and cancer. Stem Cells, 2011; 29:389–396.
8.
MishraD, SinghS, and NarayanG: Role of B cell development marker CD10 in cancer progression and prognosis. Mol Biol Int, 2016; 2016:4328697.
9.
HabischHJ, SchmidB, von ArnimCA, LudolphAC, BrennerR, and StorchA: Efficient processing of Alzheimer's disease amyloid-Beta peptides by neuroectodermally converted mesenchymal stem cells. Stem Cells Dev, 2010; 19:629–633.
10.
ShahniA, SaudM, SiddiquiS, and MukrySN: Expression of aberrant antigens in hematological malignancies: A single center experience. Pak J Med Sci, 2018; 34:457–462.
11.
ChuangSS, HuangWT, HsiehPP, JungYC, YeH, DuMQ, LuCL, ChoCY, HsiaoSC, HsuYH, and LinKJ: Sporadic paediatric and adult Burkitt lymphomas share similar phenotypic and genotypic features. Histopathology, 2008; 52:427–435.
LangnerC, RatschekM, RehakP, SchipsL, and ZigeunerR: CD10 is a diagnostic and prognostic marker in renal malignancies. Histopathology, 2004; 45:460–467.
14.
KadotaK, BuitragoD, LeeMC, Villena-VargasJ, SimaCS, JonesDR, TravisWD, and AdusumilliPS: Tumoral CD10 expression correlates with high-grade histology and increases risk of recurrence in patients with stage I lung adenocarcinoma. Lung Cancer, 2015; 89:329–336.
15.
Dall'EraMA, TrueLD, SiegelAF, PorterMP, SherertzTM, and LiuAY: Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol, 2007; 7:3.
16.
FleischmannA, RochaC, Saxer-SekulicN, ZlobecI, SauterG, and ThalmannGN: High CD10 expression in lymph node metastases from surgically treated prostate cancer independently predicts early death. Virchows Arch, 2011; 458:741–748.
17.
MokhtariM, and AmeriF: Diagnostic value of CD-10 marker in differentiating of papillary thyroid carcinoma from benign thyroid lesions. Adv Biomed Res, 2014; 3:206.
18.
LiQ, WangY, XuL, WangL, GuoY, and GuoC: High level of CD10 expression is associated with poor overall survival in patients with head and neck cancer. Int J Oral Maxillofac Surg, 2021; 50:857–864.
19.
JangTJ, ParkJB, and LeeJI: The expression of CD10 and CD15 is progressively increased during colorectal cancer development. Korean J Pathol, 2013; 47:340–347.
20.
LeeKW, SungCO, KimJH, KangM, YooHY, KimHH, UmSH, and KimSH: CD10 expression is enhanced by Twist1 and associated with poor prognosis in esophageal squamous cell carcinoma with facilitating tumorigenicity in vitro and in vivo. Int J Cancer, 2015; 136:310–321.
21.
KajiyamaH, ShibataK, TerauchiM, MoritaT, InoK, MizutaniS, and KikkawaF: Neutral endopeptidase 24.11/CD10 suppresses progressive potential in ovarian carcinoma in vitro and in vivo. Clin Cancer Res, 2005; 11:1798–1808.
22.
Thomas-PfaabM, AnnereauJP, MunschC, GuilbaudN, GarridoI, PaulC, BroussetP, LamantL, and MeyerN: CD10 expression by melanoma cells is associated with aggressive behavior in vitro and predicts rapid metastatic progression in humans. J Dermatol Sci, 2013; 69:105–113.
23.
KennyAJ, O'HareMJ, and GustersonBA: Cell-surface peptidases as modulators of growth and differentiation. Lancet, 1989; 2:785–787.
24.
TakeiJ, KanekoMK, OhishiT, HosonoH, NakamuraT, YanakaM, SanoM, AsanoT, SayamaY, KawadaM, HaradaH, and KatoY: A defucosylated anti‑CD44 monoclonal antibody 5‑mG2a‑f exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma. Oncol Rep, 2020; 44:1949–1960.
25.
TakeiJ, KanekoMK, OhishiT, KawadaM, HaradaH, and KatoY: A novel anti-EGFR monoclonal antibody (EMab-17) exerts antitumor activity against oral squamous cell carcinomas via antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Oncol Lett, 2020; 19:2809–2816.
26.
NixonJ, NewboldP, MustelinT, AndersonGP, and KolbeckR: Monoclonal antibody therapy for the treatment of asthma and chronic obstructive pulmonary disease with eosinophilic inflammation. Pharmacol Ther, 2017; 169:57–77.
27.
CruzE, and KayserV: Monoclonal antibody therapy of solid tumors: Clinical limitations and novel strategies to enhance treatment efficacy. Biologics, 2019; 13:33–51.
28.
KhannaV, PanyamJ, and GriffithTS: Exploiting antibody biology for the treatment of cancer. Immunotherapy, 2020; 12:255–267.
29.
TakahashiA, SasakiH, KimSJ, TobisuK, KakizoeT, TsukamotoT, KumamotoY, SugimuraT, and TeradaM: Markedly increased amounts of messenger RNAs for vascular endothelial growth factor and placenta growth factor in renal cell carcinoma associated with angiogenesis. Cancer Res, 1994; 54:4233–4237.
30.
ChoueiriTK, EscudierB, PowlesT, MainwaringPN, RiniBI, DonskovF, HammersH, HutsonTE, LeeJL, PeltolaK, RothBJ, BjarnasonGA, GecziL, KeamB, MarotoP, HengDY, SchmidingerM, KantoffPW, Borgman-HageyA, HesselC, ScheffoldC, SchwabGM, TannirNM, MotzerRJ, and InvestigatorsM: Cabozantinib versus everolimus in advanced renal-cell carcinoma. N Engl J Med, 2015; 373:1814–1823.
31.
EscudierB, PluzanskaA, KoralewskiP, RavaudA, BracardaS, SzczylikC, ChevreauC, FilipekM, MelicharB, BajettaE, GorbunovaV, BayJO, BodrogiI, Jagiello-GruszfeldA, MooreN, and investigatorsAT: Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: A randomised, double-blind phase III trial. Lancet, 2007; 370:2103–2111.
32.
RiniBI, HalabiS, RosenbergJE, StadlerWM, VaenaDA, OuSS, ArcherL, AtkinsJN, PicusJ, CzaykowskiP, DutcherJ, and SmallEJ: Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol, 2008; 26:5422–5428.
33.
NaeimF: Atlas of Hematopathology: Morphology, Immunophenotype, Cytogenetics, and Molecular Approaches. Elsevier, Waltham, MA, 2013.
34.
KatoY, and KanekoMK: A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Sci Rep, 2014; 4:5924.
35.
KanekoMK, OhishiT, KawadaM, and KatoY: A cancer-specific anti-podocalyxin monoclonal antibody (60-mG(2a)-f) exerts antitumor effects in mouse xenograft models of pancreatic carcinoma. Biochem Biophys Rep, 2020; 24:100826.
36.
MizutaniN, AbeM, KajinoK, and MatsuokaS: A new CD10 antibody inhibits the growth of malignant mesothelioma. Monoclon Antib Immunodiagn Immunother, 2021; 40:21–27.
37.
HosonoH, TakeiJ, OhishiT, SanoM, AsanoT, SayamaY, NakamuraT, YanakaM, KawadaM, HaradaH, KanekoMK, and KatoY: Anti‑EGFR monoclonal antibody 134‑mG2a exerts antitumor effects in mouse xenograft models of oral squamous cell carcinoma. Int J Mol Med, 2020; 46:1443–1452.
38.
OhishiT, KatoY, KanekoMK, OhbaSI, InoueH, HarakawaA, and KawadaM: Anti-metastatic activity of an anti-EGFR monoclonal antibody against metastatic colorectal cancer with KRAS p.G13D mutation. Int J Mol Sci, 2020; 21:6037.
39.
KuraiJ, ChikumiH, HashimotoK, YamaguchiK, YamasakiA, SakoT, TougeH, MakinoH, TakataM, MiyataM, NakamotoM, BuriokaN, and ShimizuE: Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines. Clin Cancer Res, 2007; 13:1552–1561.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
